·威尔布兰德病2A型:一个更新
Omid Seidizadeh1, Luciano Baronciani2, Pier Mannuccio Mannucci3
1Internal Medicine, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy.
Seminars in thrombosis and hemostasis
|December 26, 2025
概括
2A型威尔布兰德病 (VWD) 涉及缺陷的威尔布兰德因子 (VWF),导致血小板粘附受损和严重出血. 诊断需要功能测定,多分子分析和基因测试才能有效管理.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- ·威尔布兰德病 (VWD) 是最常见的遗传性出血障碍,由功能障碍或缺少·威尔布兰德因子 (VWF) 引起.
- 2A型VWD代表了一种质性缺陷,其特征是受损的VWF依赖性血小板粘附,与缺乏高和中等分子重量的VWF多元器件有关.
研究的目的:
- 提供2A型VWD的全面审查,包括其流行病学,病理生理学,临床表现,诊断方法,分子基础和治疗策略.
- 更新目前对VWF结构缺陷如何影响多分子组合,蛋白质分解裂变和连接体相互作用的理解.
主要方法:
- 对2A型VWD现有文献的审查.
- 诊断方法的分析,包括功能测试,VWF多元分析和遗传测试.
- 检查分子和结构研究,阐明VWF变体的功能.
主要成果:
- 2A型VWD与VWF活性/抗原和原结合/抗原比率的降低有关.
- 潜在的缺陷源于受损的VWF多元组件或ADAMTS13.13增加的VWF裂变.
- 临床表现包括显著的粘膜皮肤出血,诊断得到了亚型特定突变的遗传识别的支持.
结论:
- 2A型VWD需要一个多方面的诊断方法,结合功能,结构和遗传分析.
- 了解VWF缺陷的分子基础对于开发向疗法至关重要.
- 管理策略是根据出血的严重程度量身定制的,涉及德斯莫普林素和VWF替代疗法.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K
Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
317
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
317
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Cardiomyopathy II: Dilated Cardiomyopathy
431
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431


